Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur J Clin Microbiol Infect Dis ; 32(9): 1129-33, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23504236

RESUMO

The purpose of this investigation was to evaluate the effectiveness of posterior pharyngeal and nasopharyngeal swabs in identifying and quantifying meningococcal carriage. Two swab samples were obtained from 564 healthy adolescents aged 15-19 years, the first taken from the posterior pharyngeal wall through the mouth and the second through the nose. Bacterial genomic DNA was extracted and screened for Neisseria meningitidis by means of two separate singleplex real-time polymerase chain reactions (real-time PCRs) in order to identify the CtrA and sodC genes. Subsequently, N. meningitidis-positive samples underwent a further singleplex real-time PCR in order to determine the N. meningitidis serogroup, and the DNA was quantified by means of standard curves. Thirty-seven subjects (6.6 %) were found to be carriers of N. meningitidis. The most frequently carried serogroup was serogroup B (15 cases, 40.5 %); serogroups A, Y, X, W135 and Z were found in, respectively, two (5.4 %), five (13.5 %), four (10.8 %), three (8.1 %) and one subject (2.7 %); the serogroup was not identified in seven cases. The detection of carrier status was significantly more frequent using posterior pharyngeal swabs (5.3 % vs. 2.1 %; p = 0.004), which also contained a significantly larger number of N. meningitidis genomic copies (4.91 ± 1.39 vs. 2.50 ± 0.8 log10 genomic copies/mL; p < 0.001). Posterior pharyngeal swabs seem to be better than nasopharyngeal swabs for detecting N. meningitidis carriage in large-scale epidemiological studies because they identify a significantly larger number of pathogen carriers and recover a significantly larger amount of bacterial DNA.


Assuntos
DNA Bacteriano/análise , Infecções Meningocócicas/diagnóstico , Nasofaringe/microbiologia , Adolescente , Carga Bacteriana , Proteínas de Bactérias/genética , Portador Sadio/microbiologia , Técnicas e Procedimentos Diagnósticos , Feminino , Humanos , Masculino , Infecções Meningocócicas/microbiologia , Neisseria meningitidis/genética , Neisseria meningitidis/isolamento & purificação , Reação em Cadeia da Polimerase em Tempo Real , Adulto Jovem
2.
Eur Rev Med Pharmacol Sci ; 15(11): 1328-35, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22195368

RESUMO

BACKGROUND AND OBJECTIVES: Calprotectin is a protein especially expressed in neutrophil cytosol. In the last few years, Fecal calprotectin (FC) turned out to be a direct marker of gastrointestinal inflammation. Because of the simplicity of the method, it has been studied in several gastroenterologic diseases but no data are available about its concentration in children with small intestinal bacterial overgrowth (SIBO), a complex and not well known condition defined by an excessive germs proliferation, especially anaerobic, in the small bowel, and characterized by dyspeptic and malabsorption symptoms. The aim of this study was to evaluate FC values in children with SIBO, comparing to healthy subjects, in order to clarify if an inflammatory process coexists with SIBO. MATERIALS AND METHODS: We enrolled fifty-eight children affected by SIBO, as diagnosed by Lactulose Breath Test (LBT). They were assessed for FC values on stool samples. We compared them with a control population of 60 healthy children. RESULTS: In SIBO patients, a median value of 36.0 mg/kg and a mean value +/- SD of 43.0 +/- 31.6 mg/kg were calculated, while in healthy controls the median value was 29.5 mg/kg and the mean value +/- SD was 35.7 +/- 20.7 mg/kg, showing no statistically significant differences between the two groups (p = 0.07). CONCLUSIONS: FC values are negative in children affected by SIBO, not differing from those obtained in healthy children, suggesting that no subclinical intestinal inflammation involving neutrophils occurs in patients with higher proliferation of bacteria in the small bowel. The presence of high FC levels in children affected by SIBO might not be caused by bacterial overgrowth itself and, in this case, another cause should be investigated.


Assuntos
Fezes/química , Infecções/microbiologia , Enteropatias/microbiologia , Intestino Delgado/microbiologia , Complexo Antígeno L1 Leucocitário/análise , Testes Respiratórios , Criança , Feminino , Humanos , Inflamação/patologia , Enteropatias/patologia , Intestino Delgado/patologia , Lactulose/análise , Masculino , Estudos Prospectivos
3.
Eur Rev Med Pharmacol Sci ; 10(5): 229-34, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17121315

RESUMO

OBJECTIVE: To classify a cohort of Italian patients categorized as affected with juvenile idiopathic arthritis (JIA) according to the revised 2001 Edmonton International League of Associations for Rheumatology (ILAR) criteria. METHODS: Eighty-five patients with JIA firstly framed depending on traditional criteria during the last ten years were reallocated according to the JIA revised criteria proposed in 2001 by ILAR in Edmonton. RESULTS: The revision consented to define the following distribution of patients: 28.2% systemic, 55.3% oligoarticular and 11.8% polyarticular forms; only one child was defined as having psoriatic arthritis, one child with enthesitis-associated arthritis and two with the undifferentiated form of JIA. DISCUSSION: The 97.6% of the recruited patients were strictly classified according to the Edmonton ILAR criteria, demonstrating a very low number of patients whose arthritis could not be assigned to any JIA category due to unfulfillment of the required criteria.


Assuntos
Artrite Juvenil/classificação , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Lactente , Itália , Masculino , Reumatologia , Sociedades Médicas
4.
Eur Rev Med Pharmacol Sci ; 10(4): 163-71, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16910345

RESUMO

Familial Mediterranean fever (FMF) is characterized by recurrent self-limiting flares of fever in the absence of pathogens, autoantibodies or antigen specific T cells and is inherited as an autosomal recessive trait probably deriving from common ancestors of Armenian, Jew, Turk and Arab origin. The underlying pathogenetic mechanisms of FMF have not been fully interpreted, but mutations in the gene MEFV encoding pyrin, a natural repressor of proinflammatory molecules, result in uncontrolled relapsing systemic inflammation, increased leukocyte migration to serosal membranes or joints and inappropriate response to inflammatory stimuli. FMF heterogeneous phenotypic expression could originate both from allelic heterogeneity or from the existence of modulating genes. Proper diagnosis of FMF is needed to begin both specific clinical management and treatment based on continuous prophylactic administration of colchicine, preventing flares or at least the onset of amyloidosis.


Assuntos
Febre Familiar do Mediterrâneo/diagnóstico , Febre Familiar do Mediterrâneo/tratamento farmacológico , Periodicidade , Amiloidose/prevenção & controle , Anti-Inflamatórios/uso terapêutico , Criança , Colchicina/uso terapêutico , Proteínas do Citoesqueleto/genética , Diagnóstico Diferencial , Febre Familiar do Mediterrâneo/epidemiologia , Febre Familiar do Mediterrâneo/genética , Genótipo , Humanos , Mutação , Pirina , Qualidade de Vida
5.
Eur Rev Med Pharmacol Sci ; 10(2): 53-9, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16705949

RESUMO

Macrophage activation syndrome is a rare and potentially fatal complication of many childhood pathological settings, most frequently reported in systemic onset-juvenile idiopathic arthritis. The disruption of the macrophage-lymphocyte interaction leads to uncontrolled proliferation of highly activated macrophages and T lymphocytes. The syndrome comprises a heterogeneous group of disorders featuring sepsis-like characteristics typically combined with impaired function of natural killer cells and cytotoxic T-cells, haemophagocytosis and hypercytokinemia, often resulting in fatal multiple organ failure. The clinical picture shows high grade fever, hepatosplenomegaly, pancytopenia, lymphoadenopathy, central nervous system involvement and consumptive coagulopathy. Macrophage activation syndrome is associated with high mortality: even though diagnostic criteria have been proposed, definite diagnosis can be a challenge for clinicians, especially in early phases. There is no standardized therapeutic protocol for macrophage activation syndrome, but it is widely recognized that aggressive treatment strategies might strongly influence prognosis. First line-therapy is usually represented by parenteral administration of high dose-corticosteroids, whilst cyclosporine is added in the steroid-resistant cases. In this paper we provide clinical clues and summarize the most recent studies about pathophysiology and management suggestions for macrophage activation syndrome.


Assuntos
Anti-Inflamatórios/uso terapêutico , Ciclosporina/uso terapêutico , Imunossupressores/uso terapêutico , Linfo-Histiocitose Hemofagocítica/terapia , Ativação de Macrófagos/efeitos dos fármacos , Metilprednisolona/uso terapêutico , Adolescente , Anti-Inflamatórios/administração & dosagem , Artrite Juvenil/complicações , Criança , Quimioterapia Combinada , Humanos , Lactente , Infusões Intravenosas , Linfo-Histiocitose Hemofagocítica/etiologia , Linfo-Histiocitose Hemofagocítica/genética , Linfo-Histiocitose Hemofagocítica/patologia , Glicoproteínas de Membrana/genética , Metilprednisolona/administração & dosagem , Perforina , Proteínas Citotóxicas Formadoras de Poros , Síndrome
6.
Childs Nerv Syst ; 22(4): 334-7, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16525848

RESUMO

INTRODUCTION: Chronic infantile neurologic, cutaneous, articular (CINCA) syndrome is a rare congenital autoinflammatory disease characterized by neonatal-onset chronic meningitis, hydrocephalus, sensorineural hearing loss, persistent urticarial rash, deforming arthritis, and recurrent fever. This clinical entity is believed to result from dysregulation of cytokine production. No recommended treatment protocol exists so far for CINCA syndrome. CASE REPORT: We report a 7-year-old child affected with CINCA syndrome in whom no therapy had resulted effective. Anakinra, an interleukin-1-receptor antagonist, was administered in a 1-year period with complete inflammatory symptom remission and dramatically ameliorated laboratory tests. This optimal response has been supported by the demonstration of a stabilized hydrocephalus upon magnetic resonance imaging and by an overall improvement of the neurodevelopmental issues. DISCUSSION: This paper emphasizes and discusses the medical approach with anakinra in CINCA syndrome presenting with hydrocephalus in which a consistent control of the neurological picture can be obtained.


Assuntos
Artrite/complicações , Hidrocefalia/tratamento farmacológico , Fatores Imunológicos/uso terapêutico , Proteína Antagonista do Receptor de Interleucina 1/uso terapêutico , Urticária/complicações , Artrite/imunologia , Criança , Pré-Escolar , Doença Crônica , Febre/complicações , Febre/imunologia , Perda Auditiva Neurossensorial/complicações , Perda Auditiva Neurossensorial/imunologia , Humanos , Hidrocefalia/complicações , Hidrocefalia/imunologia , Doenças do Sistema Imunitário/complicações , Doenças do Sistema Imunitário/tratamento farmacológico , Doenças do Sistema Imunitário/imunologia , Lactente , Recém-Nascido , Masculino , Meningite/complicações , Meningite/imunologia , Síndrome , Resultado do Tratamento , Urticária/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA